https://www.selleckchem.com/products/arq-197.html
with a tendency toward higher inflammatory response in the EVAR patients through the first 2 years. Clinical trials have demonstrated sustained benefits of drug-coated balloon (DC angioplasty compared with noncoated balloon angioplasty in symptomatic peripheral artery disease (PAD) presenting with femoropopliteal (FP) artery disease. However, there is still controversy whether particulate embolization caused by crystalline paclitaxel, the so-called "downstream effect," is adversely associated with clinical outcomes after use of FP DCB
Like
Comment
Share
